secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0001628280-23-019654
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia licenses Vafseo to Medice for Europe, Australia; $10M upfront, up to $100M milestones
--------------------------------------------------------------------------------

- Medice gets exclusive rights to market Vafseo (vadadustat) for anemia in CKD dialysis patients in EEA, UK, Switzerland, Australia.
- Akebia receives $10M upfront, up to $100M in commercial milestones, and tiered royalties of 10-30% of net sales.
- Akebia retains 70% of net profit from non-dialysis population if it develops that indication; Medice commercializes both.
- Vafseo approved in 33 countries; regulatory opinions expected in Switzerland and Australia later in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000162828023019654/0001628280-23-019654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000162828023019654/akba-20230524.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-019654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer